Clover Health exec sells 5,833 shares under 10b5-1

Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 5,833 shares of Class A common stock in an open-market transaction at a weighted average price of $1.91 per share.

Rhea-AI Filing Summary

Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 5,833 shares of Class A common stock in an open-market transaction at a weighted average price of $1.91 per share. The shares were sold in multiple trades between $1.87 and $1.96 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, Reynoso directly holds 2,716,735 Class A shares.

Insider Trade Summary 10b5-1

Net Seller: 5,833 shares

Net Sell 1 txn

Insider Reynoso Jamie L.

Role CEO, Medicare Advantage

Sold 5,833 shs ($11K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	5,833	$1.91	$11K

Holdings After Transaction: Class A Common Stock — 2,716,735 shares (Direct)

Footnotes (1)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.96, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks:

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Clover Health (CLOV) report for Jamie L. Reynoso?

Clover Health reported that executive Jamie L. Reynoso sold 5,833 Class A common shares. The sale was an open-market transaction under a Rule 10b5-1 trading plan, reflecting a small portion of her total direct holdings.

At what price did Jamie L. Reynoso sell Clover Health (CLOV) shares?

Jamie L. Reynoso sold Clover Health shares at a weighted average price of $1.91 per share. Individual trades occurred in a price range from $1.87 to $1.96, as disclosed in the Form 4 footnote.

How many Clover Health (CLOV) shares does Jamie L. Reynoso hold after this sale?

Following the reported sale, Jamie L. Reynoso directly holds 2,716,735 Class A common shares. This indicates the 5,833 shares sold represent a small fraction of her overall direct position in Clover Health stock.

Was the Clover Health (CLOV) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected under a Rule 10b5-1 trading plan adopted by Jamie L. Reynoso on March 13, 2025. Such pre-arranged plans automate trading and can reduce the significance of trade timing.

What role does Jamie L. Reynoso hold at Clover Health (CLOV)?

Jamie L. Reynoso serves as CEO, Medicare Advantage at Clover Health. Her Form 4 filing reflects an open-market sale of 5,833 Class A shares while retaining more than 2.7 million shares in direct ownership after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 06:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reynoso Jamie L.

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Medicare Advantage

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/18/2026		S		5,833(1)	D	$1.91	2,716,735	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.96, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks:

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)